Nicox Sa · EURONEXT:ALCOX
Nicox Sa — Investor Presentation (July 2024)
28 slides from Nicox Sa's investor presentation, Jul 18, 2024
Slide 1: Nicox Corporate Presentation
Nicox Corporate Presentation An international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health July 18, 2024
Slide 2: Forward-Looking statements
Forward-Looking statements This document has been prepared by Nicox SA and may not be reproduced or distributed, in whole or in part. The information contained in this document has not been independently verified and no representation, warranty or undertaking, expressed or implied, is made as to, an
Slide 3: Progress in achieving value inflection points expected for 2024-2025
Progress in achieving value inflection points expected for 2024-2025 Appointment of Gavin Spencer as Chief Executive Officer Value proposition of NCX 470 confirmed through Kowa partnership Restructuring of debt agreements with BlackRock Recent Highlights Streamlining costs to concentrate on NCX 470
Slide 4: Consistently delivering innovations in ophthalmology
Consistently delivering innovations in ophthalmology ... stage Phase 3 development al partnerships with r 1 ophthalmology players ep ophthalmology experience >» A potentially differentiated profile targeting ~$6bn worldwide glaucoma market Positive results from the first Phase 3 trial’, Mont Blanc,
Slide 5: Upcoming milestones
Upcoming milestones Several positive milestones in 2024 and 2025 NCX 470 ** Completion of recruitment of U.S. patients Q4 2024 * Denali results — H2 2025 ** Estimated worldwide sales over $300 million! ZERVIATE * Upcoming approval in China “ Estimated Chinese sales up to $100 million? * Ongoing busi
Slide 6: An innovative portfolio led by NCX 470, a derisked product candidate
An innovative portfolio led by NCX 470, a derisked product candidate with global potential Stages of Development 3 Product Candidates Preclinical Phase 1 Phase 2 Phase 3 NDA Marketed = Status Denali topline results expected NCX 470 | NO-donating bimatoprost eye drops in H2 2025 Glaucoma & Ocular Hyp
Slide 7: Glaucoma: a worldwide ophthalmic condition with unmet medical needs
Glaucoma: a worldwide ophthalmic condition with unmet medical needs Elevated IOP* contributes to irreversible optic nerve damage, Leading to progressive vision Loss normal aqueous humor outflow \ vitreous: anterior chamber ens —+ optic nerve head posterior chamber healthy eye chamber damage to the o
Slide 8: Unmet medical needs for glaucoma treatment
Unmet medical needs for glaucoma treatment ¥ 40% of patients do not achieve their target IOP on existing monotherapies' V Tolerability issues with some medications lead to discontinuations, Despite having well established first-line therapies, including the standard-of-care, latanoprost, patients do
Slide 9: NCX 470 acts through a dual mechanism for IOP lowering
NCX 470 acts through a dual mechanism’ for IOP lowering Non-clinical optic nerve/retinal damage models also demonstrate potentially beneficial retinal effects? Two pathways for Primary or conventional aqueous humor outflow outflow normally we Stimulated by accounts for ~60% to énitrooyjnexancieacia
Slide 10: Positive NCX 470 Mont Blanc topline results
Positive NCX 470 Mont Blanc topline results’? Phase 3 clinical program intended to support planned U.S. & China NDA submissions Designed to demonstrate safety and efficacy of NCX 470 0.1% vs. Latanoprost 0.005%, defined by IOP reduction from time-matched baseline at pre-established time points MONT
Slide 11: Mont Blanc dosage arms schematic
1. This schematic reflects the dosage arms which continued in the trial and do not include the NCX 470 0.065% dose which was only in the adaptive design portion of the trial
Slide 12: IOP reduction and risk of vision loss progression
As published in the landmark EMGT study “…each mmHg of decreased IOP was related to an approximately 10% lowering [of risk of vision loss progression]”1 1. This data reflects the dosage arms which continued in the trial and do not include the NCX 470 0.065% dose which was only in the adaptive design
Slide 13: NCX 470 0.1% vs Latanoprost 0.005% results
NCX 470 0.1%: N = 328 Latanoprost 0.005%: N = 333 • Denotes statistically significant differences vs latanoprost (p<0.049) • Fechtner et al., AJO, published, 2024 - https://doi.org/10.1016/j.ajo.2024.03.002
Slide 14: Statistically significant differences vs latanoprost
• * * * * • • * Denotes statistically significant differences vs latanoprost (p<0.049)
Slide 15: NCX 470 was well tolerated
• • • • ≤ • • NCX 470 was well • • • 1. This data reflects the dosage arms which continued in the trial and do not include the NCX 470 0.065% dose which was only in the adaptive design portion of the trial.
Slide 16: NCX 470 presentations at key ophthalmology conferences
NCX 470 - Presentations at key ophthalmology conferences OM ERAN + Poster 1: Intraocular Pressure Reduction with NCX 470 versus Latanoprost Across the Spectrum of Baseline Intraocular SOCIETY Pressures + Poster 2: Intraocular Pressure Reduction with NCX 470 versus Latanoprost In Previously Treated V
Slide 17: Conclusion: NCX 470 0.1% well-tolerated and lowered IOP more than latanoprost
Conclusion: The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with OAG or OHT at all 6 time points. With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important first-li
Slide 18: U.S. glaucoma clinical advisory board with leading experts
U.S. glaucoma clinical advisory board with leading experts DR. ROBERT D. FECHTNER, MD, CHAIRMAN Professor and Chair of the Department of Ophthalmology at SUNY Upstate Medical University, Syracuse, NY DR. SANJAY G. ASRANI, MD Professor of Ophthalmology at Duke University in Durham, North Carolina, an
Slide 19: Value proposition of NCX 470
< fe} S 2 Value proposition of NCX 470 Novel molecule with competitive positive impact on lowering intraocular pressure (IOP), the leading cause of glaucoma Positive pivotal Phase 3 topline results from the Mont Blanc trial!23 First non-combination product to demonstrate statistical non-inferiority
Slide 20: NCX 470 patents and peak sales potential
**Subject to securing a U.S. commercial partner • Composition of matter patent to 2029 expected to be extended to 2034 in the United States and formulation patent to 2039. Additional marketing exclusivity may be available based on the status as a New Chemical Entity • Peak annual net sales potential
Slide 21: Ocumension Therapeutics partner
Portfolio of 25 Listed on the 444 employees, Based in China products with Hong Kong stock including 232 in Created in 2018 10 commercialised exchange since commercial Dedicated to $34 million revenue 2020 ophthalmology in 2023 (+55%) $600 million market cap • • •
Slide 22: Kowa partner
Founded in Japan in 1894 ~8000 employees The pharmaceutical Team of medical Active worldwide with an annual sector is an representatives in in multiple group revenue of important one with Japan and a domains including $4.9 billion an international franchise in life sciences presence glaucoma • • •
Slide 23: Future commercialization of NCX 470
Future commercialization of NCX 470 To secure the Long-term future of the Company * The Company is considering a number of options to ensure the commercialization of NCX 470 and concretize the future strategy: * New license agreements * — Joint venture structures with companies having complementary
Slide 24: Existing commercial products: VYZULTA and ZERVIATE
.) Existing commercial products VYZULTA BAUSCH +LOMB Marketed in >15 countries and territories, including the U.S. ¢) OcuMension WH Approval expected in China in 20247 v 5% to 9% royalties on annual net sales v Potential for up to $17.2 million in sales milestones by Ocumension v Will be manufacture
Slide 25: A refocused global leadership team
A refocused global leadership team Gavin Spencer Sandrine Gestin Doug Hubatsch Chief Executive Officer VP, Finance and EVP, Chief Scientific Officer HR tb NOVARTIS tb NOVARTIS t+) BOOTS HEALTHCARE INTERNATIONAL Sonia Benhamida Observer BlackRock Gavin Spencer Damian Marron Michele Garufi Marc Le Boz
Slide 26: Financial highlights
Financial highlights Cash balance expected to support current operations through to February 2025 Financial Position and Ownership of the Nicox Group’ Cash, Cash Equivalents as at 30 June 2024 €7.8 million Long term debt as at 30 June 2024? €20.5 million Cash runway? February 2025 Outstanding Shares
Slide 27: Investment highlights
Investment highlights proven track record in clinical development and business develo * Two product approvals in the U.S., one pending in China * Business development deals in the U.S., Japan, China, and globally with Tier 1 companies vy NCX 470, a derisked, late-stage development program * Positive
Slide 28: Nicox S.A.
28 Nicox S.A. Sundesk Sophia Antipolis Emerald Square Batiment C rue Evariste Galois, 06410 Biot, France T: +33 (0)4 97 24 53 00 nicox visible science COMMUN ications@ nicox.com WWww.nicox.com, (@